Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-922-0718
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees118
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable
Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions
What is Gossamer Bio's stock symbol?
Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."
How were Gossamer Bio's earnings last quarter?
Gossamer Bio Inc (NASDAQ:GOSS) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.10. View Gossamer Bio's Earnings History.
When is Gossamer Bio's next earnings date?
What price target have analysts set for GOSS?
7 brokerages have issued twelve-month price objectives for Gossamer Bio's stock. Their forecasts range from $25.00 to $32.00. On average, they anticipate Gossamer Bio's stock price to reach $29.17 in the next year. This suggests a possible upside of 113.1% from the stock's current price. View Analyst Price Targets for Gossamer Bio.
What is the consensus analysts' recommendation for Gossamer Bio?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gossamer Bio.
Has Gossamer Bio been receiving favorable news coverage?
News stories about GOSS stock have been trending positive on Wednesday, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gossamer Bio earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Gossamer Bio.
Are investors shorting Gossamer Bio?
Gossamer Bio saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,890,000 shares, an increase of 11.6% from the January 15th total of 4,380,000 shares. Based on an average daily volume of 588,400 shares, the short-interest ratio is presently 8.3 days. Currently, 11.4% of the company's shares are sold short. View Gossamer Bio's Current Options Chain.
Who are some of Gossamer Bio's key competitors?
Some companies that are related to Gossamer Bio include Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Alkermes (ALKS), Agios Pharmaceuticals (AGIO), PPD (SDGR), Zai Lab (ZLAB), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Genmab A/S (GMAB), Axsome Therapeutics (AXSM) and Emergent Biosolutions (EBS).
What other stocks do shareholders of Gossamer Bio own?
Who are Gossamer Bio's key executives?
Gossamer Bio's management team includes the folowing people:
- Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)
- Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)
- Mr. Bryan Giraudo, Chief Financial Officer (Age 43)
- Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)
- Dr. Jakob Dupont, Chief Medical Officer (Age 54)
When did Gossamer Bio IPO?
(GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.
Who are Gossamer Bio's major shareholders?
Gossamer Bio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (3.31%), Alliancebernstein L.P. (2.64%), State Street Corp (2.49%), Victory Capital Management Inc. (1.96%), Victory Capital Management Inc. (1.94%) and Franklin Resources Inc. (0.91%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid, Russell J Cox and Waage Christian. View Institutional Ownership Trends for Gossamer Bio.
Which institutional investors are selling Gossamer Bio stock?
GOSS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Alliancebernstein L.P., UBS Group AG, Franklin Resources Inc. and Tower Research Capital LLC TRC . Company insiders that have sold Gossamer Bio company stock in the last year include Fund V Gp LP Omega, Jakob Dupont and Luisa Salter-Cid. View Insider Buying and Selling for Gossamer Bio.
Which institutional investors are buying Gossamer Bio stock?
GOSS stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Farallon Capital Management LLC, Alyeska Investment Group L.P., Boxer Capital LLC, Victory Capital Management Inc., Goldman Sachs Group Inc., Victory Capital Management Inc. and Jacobs Levy Equity Management Inc.. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, Russell J Cox and Waage Christian. View Insider Buying and Selling for Gossamer Bio.
How do I buy shares of Gossamer Bio?
Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Gossamer Bio's stock price today?
One share of GOSS stock can currently be purchased for approximately $13.69.
How big of a company is Gossamer Bio?
Gossamer Bio has a market capitalization of $904.09 million. The company earns $-146,970,000.00 in net income (profit) each year or ($22.59) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe.View Additional Information About Gossamer Bio.
What is Gossamer Bio's official website?
How can I contact Gossamer Bio?
Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718.
MarketBeat Community Rating for Gossamer Bio (NASDAQ GOSS)
MarketBeat's community ratings are surveys of what our community members think about Gossamer Bio and other stocks. Vote "Outperform" if you believe GOSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
